Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort
Authors' conclusion
With the development of new RA therapeutics, overall treatment outcomes advanced in the past decade.
Study context
- Population
- Rheumatoid arthritis (RA) patients in the KURAMA observational cohort, 2012–2021; patients initiating b/tsDMARDs1,816 initiated b/tsDMARDs
- Participants
- 5,070 patients
- Exposure
- b/tsDMARDs compared with each other; trends in RA management 2012–2021
- Outcome
- Trends in RA management and outcomes, 2012–2021
Methodological detailsannual cross-sectional data, longitudinal data, mixed-effect models with background adjustment
- Annual cross-sectional data
- Longitudinal data
- Mixed-effect models with background adjustment
Main finding
As reported in the abstract
- b/tsDMARD use increased, GC use decreased from 2012 to 2021
- Disease activity and functional disability measures improved over time
- Percentage of tsDMARD prescriptions considerably increased
- After adjustment for patient characteristics, annual change of RA disease activity and functional disability significantly better from 2012 to 2021
Observational data: associations, not effects.
Further findings
Treatment outcomes between b/tsDMARDs
- All b/tsDMARDs showed clinical improvements in disease activity and functional disability
- TNFi better short-term improvements in b/tsDMARD-naïve patients
- IL6Ri significant long-term benefits
- IL6Ri better retention rates in switched patients
Original publication
Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort. Arthritis Res Ther. Published 9 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →